HomeAbout usProductsInvestor centreMedia centrePartneringCareers

Company highlights


  • Track record of advancing products through trials, gaining FDA approval and acquiring/licensing products
  • Piperline of cancer drugs including one in phase III and one in phase II
  • Attractive divestible preclinical programme in auto-immune diseases
  • ~£45 million at end Feb 2010 (unaudited)

 

Delivered by Investis and link to website (opens in a new window)